Glutamine and recombinant human growth hormone protect intestinal barrier function following portal hypertension surgery.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To evaluate the effects of combined treatment of glutamine (Gln) and recombinant human growth hormone(rhGH) on intestinal barrier function following portal hypertension surgery.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Forty two patients after portal hypertension surgery were randomly assigned into 2 groups: control group (n = 20) and supplemental group (adding Gln and rhGH, n = 22).

Every patient received isocaloric and isonitrogenous standard total parenteral nutrition (TPN) starting 3 d after surgery for 7 d.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

This study was designed as a prospective, randomized and controlled clinical trial.

Blood samples were obtained before surgery and at the 3rd and 10th day postoperatively.

Host immunity was evaluated by measuring levels of CD4, CD8, CD4/CD8, IgG, IgM and IgA, and the inflammatory responses were determined by assessing IL-2, TNF-alpha and C-reactive protein (CRP) levels.

Intestinal permeability and integrity was evaluated by L/M test and histological examination, respectively.

What Was Measured

PubMed files the paper under topics including Atrophy, C-Reactive Protein, Cell Membrane Permeability, Glutamine, Human Growth Hormone, Hypertension, Portal and Immunoglobulins.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (World journal of gastroenterology), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.